Thank You for Joining Us at
EuroPCR 2026.
From Booth F18 to the symposium stage, our team engaged with healthcare professionals, researchers, partners, and peers across important conversations in coronary and peripheral intervention, clinical evidence, medical education, and real-world experience.
Presentations
at Symposium
of Engagement
Evidence Showcased
Watch the EuroPCR 2026 Symposium
For those who missed the live session in Theatre Bordeaux — the full symposium recording, "MagicTouch Sirolimus Coated Balloon for CAD and PAD Treatment: Where Evidence Meets Experience," is now available to watch in full.
Thank you to everyone who visited us, shared perspectives, and contributed to an unforgettable booth experience. These exchanges continue to strengthen our commitment to science, partnership, and patient-centred innovation.
Landmark NEJM & JACC publications shared, with 35+ trials anchoring a decade of MagicTouch evidence in coronary and peripheral intervention.
Conversations with clinicians, researchers, distributors, and partners from over a dozen countries — building bridges from the booth to the cath lab.
Every discussion, every poster, every demo — anchored in the patients whose outcomes drive everything Nanolute™ and MagicTouch stand for.
Where Our Data Took the Stage
A record of the MagicTouch evidence presented across hotline sessions, late-breaking trials, abstracts, and case corners throughout the four days of EuroPCR 2026.
Prevalence, temporal trends and characteristics of high bleeding risk patients in TRANSFORM II randomised controlled trial
Coronary bifurcation lesions side branch optimal treatment study: the BILBO multicentre study
DCB in STEMI: multicentre international registry
Sirolimus vs paclitaxel-coated balloons in STEMI: international multi-centre registry
DCB for CTO: final results of PICCOLETO X multicentre study
DES vs. DCB strategy in SVG PCI: real-world outcomes from two large UK centres
DCB in STEMI: multicentre international registry
All sessions presented at the EuroPCR 2026 congress, Palais des Congrès de Paris, 19–22 May 2026.
The Technology Behind the Evidence
NANOLUTE technology delivers polymer-free nanocarriers containing sirolimus surrounded by an encapsulation of a proprietary phospholipid carrier — improving lipophilicity and ensuring deep vessel wall penetration.
- Facilitates better adhesion of Sirolimus on the balloon surface
- Circumferential coating ensures homogeneous drug delivery
- Effective drug transfer to the deepest layer of the vessel
- Better in-tissue bioavailability of Sirolimus
A Decade
of Evidence
From CE Mark to a still-growing clinical record across coronary and peripheral indications.
MagicTouch
It's repeatedly studied.
Landmark Clinical Results
The randomised controlled trials and registries we shared from the booth and on the symposium stage — from JACC to the New England Journal of Medicine.
1. Log–rank p=0.03 | HR 0.60 (95% CI, 0.36–0.97). Preliminary before CEC adjudication.
MALE: Major Adverse Limb Events
2. –4.9% (–8.5% to –1.3%) P<0.001 for noninferiority | P=0.009 for superiority.
3. Data published in EuroIntervention Journal: DOI: 10.4244/EIJ-D-23-00966, Volume 20, Number 13.
Let's Keep the
Dialogue Going.
Didn't have enough time at Booth F18? Want a follow-up demo, detailed data package, or a deeper discussion with our clinical team? Reach out — we'd love to continue the conversation we started in Paris.